179003-02-2Relevant articles and documents
Hybrid Organic Lead Iodides: Role of Organic Cation Structure in Obtaining 1D Chains of Face-Sharing Octahedra vs 2D Perovskites
Tremblay, Marie-Hélène,Boyington, Allyson,Rigin, Sergei,Jiang, Jie,Bacsa, John,Al Kurdi, Khaled,Khrustalev, Victor N.,Pachter, Ruth,Timofeeva, Tatiana V.,Jui, Nathan,Barlow, Stephen,Marder, Seth R.
, p. 935 - 946 (2022/01/31)
((R(CH2)nNH3+ cations (R = aryl, substituted cyclohexyl; n = 1, 2) can form hybrid lead iodides that include both 2D layered perovskites of formula [R(CH2)nNH3]2PbI4 and 1D structures consisting of 1D wires of face-sharing PbI6 octahedra and having the formula [R(CH2)nNH3]PbI3 (face-sharing lead iodide chains, FSLICs). Using a series of such cations, we find that 1D FSLIC formation is favored when hydrogen bonding is possible between the ammonium moiety of one cation and a hydrogen-bond acceptor substituent of the same or another cation. A total of 16 new hybrid organic lead iodide crystal structures, 11 of which are FSLICs, are reported. The FSLIC structures can be further categorized according to the arrangement of neighboring wires. The optical properties of these materials are largely insensitive to the identity of the organic cations and to the resulting structural details. However, there is a correlation between the exciton energy and the pattern in which the wires are arranged relative to one another. Density functional theory calculations indicate that the dispersion at the top of the valence band varies depending on the relative wire arrangement.
NOVEL FERROPORTIN INHIBITORS
-
Page/Page column 137; 326; 327, (2017/05/10)
The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
HIGHLY WATER-SOLUBLE SALTS OF A SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKER AND USES THEREOF
-
Page/Page column 23, (2016/11/02)
The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.
SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF
-
Page/Page column 59, (2009/01/23)
The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no- reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
-
, (2008/06/13)
This invention relates to novel compounds containing basic and acidic termini, pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.
